Hubbry Logo
Post-translational modificationPost-translational modificationMain
Open search
Post-translational modification
Community hub
Post-translational modification
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Post-translational modification
Post-translational modification
Post-translational modification
View on Wikipedia
from Wikipedia
Post-translational modification of insulin. At the top, the ribosome translates a mRNA sequence into a protein, insulin, and passes the protein through the endoplasmic reticulum, where it is cut, folded, and held in shape by disulfide (-S-S-) bonds. Then the protein passes through the golgi apparatus, where it is packaged into a vesicle. In the vesicle, more parts are cut off, and it turns into mature insulin.

In molecular biology, post-translational modification (PTM) is the covalent process of changing proteins following protein biosynthesis. PTMs may involve enzymes or occur spontaneously. Proteins are created by ribosomes, which translate mRNA into polypeptide chains, which may then change to form the mature protein product. PTMs are important components in cell signalling, as for example when prohormones are converted to hormones.

Post-translational modifications can occur on the amino acid side chains or at the protein's C- or N- termini.[1] They can expand the chemical set of the 22 amino acids by changing an existing functional group or adding a new one such as phosphate. Phosphorylation is highly effective for controlling the enzyme activity and is the most common change after translation.[2] Many eukaryotic and prokaryotic proteins also have carbohydrate molecules attached to them in a process called glycosylation, which can promote protein folding and improve stability as well as serving regulatory functions. Attachment of lipid molecules, known as lipidation, often targets a protein or part of a protein attached to the cell membrane.

Other forms of post-translational modification consist of cleaving peptide bonds, as in processing a propeptide to a mature form or removing the initiator methionine residue. The formation of disulfide bonds from cysteine residues may also be referred to as a post-translational modification.[3] For instance, the peptide hormone insulin is cut twice after disulfide bonds are formed, and a propeptide is removed from the middle of the chain; the resulting protein consists of two polypeptide chains connected by disulfide bonds.

Some types of post-translational modification are consequences of oxidative stress. Carbonylation is one example that targets the modified protein for degradation and can result in the formation of protein aggregates.[4][5] Specific amino acid modifications can be used as biomarkers indicating oxidative damage.[6] PTMs and metal ions play a crucial and reciprocal role in regulating protein function, influencing cellular processes such as signal transduction and gene expression, with dysregulated interactions implicated in diseases like cancer and neurodegenerative disorders.[7]

Sites that often undergo post-translational modification are those that have a functional group that can serve as a nucleophile in the reaction: the hydroxyl groups of serine, threonine, and tyrosine; the amine forms of lysine, arginine, and histidine; the thiolate anion of cysteine; the carboxylates of aspartate and glutamate; and the N- and C-termini. In addition, although the amide of asparagine is a weak nucleophile, it can serve as an attachment point for glycans. Rarer modifications can occur at oxidized methionines and at some methylene groups in side chains.[8]

Post-translational modification of proteins can be experimentally detected by a variety of techniques, including mass spectrometry, Eastern blotting, and Western blotting.

PTMs involving addition of functional groups

[edit]

Addition by an enzyme in vivo

[edit]

Hydrophobic groups for membrane localization

[edit]

Cofactors for enhanced enzymatic activity

[edit]

Modifications of translation factors

[edit]

Smaller chemical groups

[edit]

Non-enzymatic modifications in vivo

[edit]

Examples of non-enzymatic PTMs are glycation, glycoxidation, nitrosylation, oxidation, succination, and lipoxidation.[16]

Non-enzymatic additions in vitro

[edit]
  • biotinylation: covalent attachment of a biotin moiety using a biotinylation reagent, typically for the purpose of labeling a protein.
  • carbamylation: the addition of isocyanic acid to a protein's N-terminus or the side-chain of Lys or Cys residues, typically resulting from exposure to urea solutions.[23]
  • oxidation: addition of one or more oxygen atoms to a susceptible side-chain, principally of Met, Trp, His or Cys residues. Formation of disulfide bonds between Cys residues.
  • pegylation: covalent attachment of polyethylene glycol (PEG) using a pegylation reagent, typically to the N-terminus or the side-chains of Lys residues. Pegylation is used to improve the efficacy of protein pharmaceuticals.

Conjugation with other proteins or peptides

[edit]

Chemical modification of amino acids

[edit]

Structural changes

[edit]

Statistics

[edit]

Common PTMs by frequency

[edit]

In 2011, statistics of each post-translational modification experimentally and putatively detected have been compiled using proteome-wide information from the Swiss-Prot database.[29] The 10 most common experimentally found modifications were as follows:[30]

Frequency Modification
58383 Phosphorylation
6751 Acetylation
5526 N-linked glycosylation
2844 Amidation
1619 Hydroxylation
1523 Methylation
1133 O-linked glycosylation
878 Ubiquitylation
826 Pyrrolidone carboxylic acid
504 Sulfation

Common PTMs by residue

[edit]

Some common post-translational modifications to specific amino-acid residues are shown below. Modifications occur on the side-chain unless indicated otherwise.

Amino Acid Abbrev. Modification
Alanine Ala or A N-acetylation (N-terminus)
Arginine Arg or R deimination to citrulline, methylation
Asparagine Asn or N deamidation to Asp or iso(Asp), N-linked glycosylation, spontaneous isopeptide bond formation
Aspartic acid Asp or D isomerization to isoaspartic acid, spontaneous isopeptide bond formation
Cysteine Cys or C disulfide-bond formation, oxidation to sulfenic, sulfinic or sulfonic acid, palmitoylation, N-acetylation (N-terminus), S-nitrosylation
Glutamine Gln or Q cyclization to pyroglutamic acid (N-terminus), deamidation to glutamic acid or isopeptide bond formation to a lysine by a transglutaminase
Glutamic acid Glu or E cyclization to pyroglutamic acid (N-terminus), gamma-carboxylation
Glycine Gly or G N-myristoylation (N-terminus), N-acetylation (N-terminus)
Histidine His or H phosphorylation
Isoleucine Ile or I
Leucine Leu or L
Lysine Lys or K acetylation, ubiquitylation, SUMOylation, methylation, hydroxylation leading to allysine, spontaneous isopeptide bond formation
Methionine Met or M N-acetylation (N-terminus), N-linked ubiquitination, oxidation to sulfoxide or sulfone
Phenylalanine Phe or F
Proline Pro or P hydroxylation
Serine Ser or S phosphorylation, O-linked glycosylation, N-acetylation (N-terminus)
Threonine Thr or T phosphorylation, O-linked glycosylation, N-acetylation (N-terminus)
Tryptophan Trp or W mono- or di-oxidation, formation of kynurenine, tryptophan tryptophylquinone
Tyrosine Tyr or Y sulfation, phosphorylation
Valine Val or V N-acetylation (N-terminus)

Databases and tools

[edit]
Flowchart of the process and the data sources to predict PTMs.[31]

Protein sequences contain sequence motifs that are recognized by modifying enzymes, and which can be documented or predicted in PTM databases. With the large number of different modifications being discovered, there is a need to document this sort of information in databases. PTM information can be collected through experimental means or predicted from high-quality, manually curated data. Numerous databases have been created, often with a focus on certain taxonomic groups (e.g. human proteins) or other features.

List of resources

[edit]
  • PhosphoSitePlus[32] – A database of comprehensive information and tools for the study of mammalian protein post-translational modification
  • ProteomeScout[33] – A database of proteins and post-translational modifications experimentally
  • Human Protein Reference Database[33] – A database for different modifications and understand different proteins, their class, and function/process related to disease causing proteins
  • PROSITE[34] – A database of Consensus patterns for many types of PTM's including sites
  • RESID[35] – A database consisting of a collection of annotations and structures for PTMs.
  • iPTMnet [36]– A database that integrates PTM information from several knowledgbases and text mining results.
  • dbPTM[31] – A database that shows different PTM's and information regarding their chemical components/structures and a frequency for amino acid modified site
  • Uniprot has PTM information although that may be less comprehensive than in more specialized databases.
    Effect of PTMs on protein function and physiological processes.[37]
  • The O-GlcNAc Database[38][39] - A curated database for protein O-GlcNAcylation and referencing more than 14 000 protein entries and 10 000 O-GlcNAc sites.

Tools

[edit]

List of software for visualization of proteins and their PTMs

  • PyMOL[40] – introduce a set of common PTM's into protein models
  • AWESOME[41] – Interactive tool to see the role of single nucleotide polymorphisms to PTM's
  • Chimera[42] – Interactive Database to visualize molecules

Case examples

[edit]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Post-translational modification

View on Grokipedia
from Grokipedia
Post-translational modifications (PTMs) are covalent changes to proteins that occur subsequent to their on ribosomes, typically involving the enzymatic addition or removal of chemical groups to specific side chains or the polypeptide backbone. These modifications, which can be reversible or irreversible, enable a single to generate multiple protein variants with diverse functions, far exceeding the coding capacity of the alone. Among the over 680 known types of PTMs, several are particularly prominent and well-studied due to their prevalence and regulatory roles. , for instance, involves the transfer of a group from ATP to , , or residues by , and its reversal by phosphatases; this dynamic process controls activity, protein-protein interactions, and signaling pathways essential for cellular responses to stimuli. attaches carbohydrate moieties to (N-linked) or / (O-linked) residues, influencing protein folding, stability, trafficking, and cell-cell recognition, with critical implications in immune responses and disease states like cancer. Ubiquitination conjugates proteins to residues, often marking targets for proteasomal degradation, thereby regulating and . Other key modifications include (addition of acetyl groups to , affecting dynamics and ), (addition of methyl groups to or , modulating protein interactions and epigenetic marks), and sumoylation (attachment of small ubiquitin-like modifier proteins, altering subcellular localization and stress responses). PTMs play indispensable roles in nearly all aspects of cellular biology, from and gene regulation to and , allowing cells to rapidly adapt to environmental changes without altering . Dysregulation of PTMs is implicated in numerous pathologies, including neurodegenerative diseases like Alzheimer's (via aberrant and ubiquitination) and cancers (through hyperactive cascades). Advances in , bioinformatics, and AI-driven prediction tools have facilitated the mapping of PTM sites across proteomes, revealing their extensive and context-dependent effects on protein function.

Fundamentals

Definition and Overview

Post-translational modifications (PTMs) are covalent alterations to newly synthesized proteins that occur following ribosomal translation, involving changes to side chains, the N- or C-termini, or the polypeptide backbone. These modifications can happen either co-translationally, as the polypeptide chain emerges from the ribosome, or post-translationally, after the full protein has been assembled. In eukaryotic cells, PTMs take place across multiple compartments, including the for cytoplasmic proteins, the endoplasmic reticulum () for initial processing of secretory and membrane proteins, and the Golgi apparatus for further maturation. In prokaryotes, lacking membrane-bound organelles, these modifications predominantly occur in the . Basic mechanisms include enzyme-catalyzed reactions, such as those mediated by kinases that transfer phosphate groups to specific residues, and non-enzymatic processes driven by spontaneous chemical reactions under physiological conditions. The historical recognition of PTMs began in the mid-20th century, with early studies in the on insulin biosynthesis revealing proteolytic processing events essential for hormone activation. A pivotal milestone occurred in the 1960s when Donald F. Steiner identified proinsulin as a precursor requiring post-translational cleavage to yield mature insulin, establishing the paradigm of precursor processing. Concurrently, in the 1970s, expanded research on demonstrated its dynamic regulatory role, solidifying PTMs as fundamental to cellular control. These modifications collectively enhance protein diversity and functionality beyond what is encoded by the alone.

Biological Significance

Post-translational modifications (PTMs) play crucial roles in regulating protein function within cells, enabling precise control over enzymatic activity, protein stability, subcellular localization, and molecular interactions. For instance, can activate or inactivate enzymes by inducing conformational changes, while ubiquitination often serves as a degradation signal through the ubiquitin-proteasomal system, targeting proteins for breakdown to maintain cellular . Acetylation and can modulate protein stability by competing with ubiquitination sites or altering recognition by ligases, as seen in the stabilization of tumor suppressor via that prevents its degradation. Additionally, PTMs like myristoylation facilitate membrane targeting for localization, and influences binding affinities in protein-protein interactions, thereby fine-tuning cellular responses to stimuli. Beyond individual regulation, PTMs vastly expand the functional diversity of the , surpassing the limitations imposed by the 20 standard and allowing for combinatorial signaling networks that integrate multiple inputs. This increased complexity arises from the addition of more than 400 known PTM types, with the number continuing to grow and exceeding 600 as of 2024 according to comprehensive databases, which can occur on multiple sites within a single protein, creating a "PTM code" that amplifies proteome information content and enables dynamic responses in pathways such as kinase cascades, where sequential propagate signals rapidly across cells. For example, multisite phosphorylation in kinase signaling networks acts as molecular switches, coordinating events like progression without requiring new protein synthesis. From an evolutionary perspective, PTMs represent ancient adaptations that permit rapid cellular adjustments to environmental changes without altering the , with many modification types tracing back to the and conserved across domains of life. Phosphorylation and sites, in particular, exhibit sequence conservation in functional motifs, such as those in transcription factors or eukaryotic signaling proteins, reflecting selective pressure for maintained regulatory roles over billions of years. This conservation underscores PTMs' role in evolving efficient, reversible mechanisms for adaptation, as evidenced by the persistence of phosphorylation sites from premetazoan lineages. Dysregulation of PTMs is strongly implicated in pathogenesis, particularly cancer, where aberrant modifications disrupt normal cellular control and promote uncontrolled proliferation. Hyperphosphorylation in key signaling pathways, such as MAPK and PI3K/AKT, driven by overactive kinases, enhances oncogenic signaling and inhibits , as observed in various malignancies. Similarly, altered ubiquitination can destabilize tumor suppressors like FOXO1 through excessive degradation, contributing to tumor growth in colon cancer. These imbalances highlight PTMs as critical therapeutic targets for restoring proper protein regulation.

Classification of PTMs

Enzymatic Additions In Vivo

Enzymatic additions refer to post-translational modifications (PTMs) that are catalyzed by specific enzymes, such as transferases, within living cells to covalently attach chemical groups to proteins, thereby modulating their function, localization, or stability. These processes occur either co-translationally, during protein synthesis on the , or post-translationally, after the polypeptide chain is fully assembled, allowing for precise in response to cellular signals. Hydrophobic group additions, including and myristoylation, enable protein anchoring to cellular membranes. involves the irreversible attachment of farnesyl (C15) or geranylgeranyl (C20) isoprenoid groups to a residue in the C-terminal CAAX motif by farnesyltransferase (FTase) or geranylgeranyltransferase I (GGTase I), respectively, followed by proteolytic cleavage of the AAX residues and carboxyl ; this modification targets proteins like Ras to lipid bilayers for signaling roles. Myristoylation, in contrast, is a co-translational irreversible where N-myristoyltransferase (NMT) attaches a saturated C14 myristoyl group from myristoyl-CoA to the N-terminal of nascent proteins bearing a Met-Gly sequence, facilitating membrane association in proteins such as Src kinases and promoting interactions with . Cofactor attachments via enzymatic PTMs incorporate essential prosthetic groups to activate enzymes. Biotinylation covalently links biotin to a specific lysine residue in carboxylases through biotin protein ligases (also known as holocarboxylase synthetase in eukaryotes), utilizing ATP to form a amide bond that positions biotin for transferring CO2 groups during carboxylation reactions, thus enabling metabolic processes like fatty acid synthesis. In heme-binding proteins, covalent attachment occurs in cytochromes c, where cytochrome c heme lyase (CCHL) catalyzes the formation of thioether bonds between the heme vinyl groups and paired cysteine residues in a CXXCH motif, stabilizing the cofactor for efficient electron transport in the mitochondrial respiratory chain. Small group additions represent some of the most dynamic enzymatic PTMs, often serving as reversible switches for signaling. entails the transfer of a γ-phosphate from ATP to the hydroxyl groups of serine, , or residues by protein kinases, which alters protein conformation, enzymatic activity, or binding affinity, as seen in the activation of glycogen synthase kinase-3 (GSK3) for metabolic regulation. N-terminal involves N-acetyltransferases (NATs), such as NatA, which co- or post-translationally add an from to the α-amino group of the N-terminal residue (often after excision), influencing protein and nuclear localization in eukaryotic proteins like actins. adds one to three methyl groups to or side chains, catalyzed by protein methyltransferases including methyltransferases (HMTs) like SET domain-containing enzymes, which modify tails to recruit complexes and regulate gene transcription. Modifications of translation factors highlight specialized enzymatic PTMs critical for protein synthesis. Hypusination uniquely modifies the lysine residue at position 50 of 5A (eIF5A) through a two-step process: deoxyhypusine synthase (DHS) transfers a butylamine group from spermidine to the ε-amino group of , forming deoxyhypusine, which is then hydroxylated by deoxyhypusine hydroxylase (DOHH) to yield hypusine, enabling eIF5A's role in elongation and formation. In , of the initiator methionyl-tRNAfMet by methionyl-tRNA formyltransferase adds a formyl group from N10-formyltetrahydrofolate to the α-amino group of , a co-translational step essential for recognizing the during initiation.

Non-Enzymatic Modifications

Non-enzymatic post-translational modifications (PTMs) occur spontaneously without enzymatic catalysis, driven by environmental factors or reactive species, and contrast with the regulated enzymatic additions that predominate in cellular homeostasis. These modifications arise from chemical reactions between proteins and endogenous metabolites or stressors, such as elevated glucose levels or reactive oxygen species (ROS), leading to alterations in protein structure, function, and stability. In vivo, they often accumulate under pathological conditions like hyperglycemia or oxidative stress, contributing to disease progression, while in vitro, they can introduce artifacts during experimental handling or serve as deliberate tools in proteomics. Glycation represents a prominent in vivo non-enzymatic PTM, where reducing sugars like glucose react with nucleophilic side chains, primarily lysines and arginines, to form advanced glycation end products (AGEs). This process, known as the , is accelerated in due to chronic , resulting in irreversible cross-links that impair protein function and promote via receptor interactions. For instance, AGEs accumulate on serum proteins and components, exacerbating vascular complications in mellitus. Similarly, protein oxidation occurs non-enzymatically when ROS, such as , oxidize cysteine residues to form sulfenic acids (sulfenylation), altering redox-sensitive signaling pathways. This modification is transient and can propagate oxidative signals but may lead to further oxidation if unchecked, as seen in cellular responses to environmental stressors. Deamidation is another spontaneous in vivo PTM, involving the hydrolysis of asparagine residues to aspartate (or isoaspartate via a succinimide intermediate), influenced by local protein sequence, pH, and temperature. This non-enzymatic conversion introduces a negative charge, potentially disrupting protein folding and enzymatic activity, and accumulates over time in long-lived proteins like crystallins in the lens. Mechanisms underlying these modifications generally involve nucleophilic attacks or radical reactions facilitated by reactive species; for oxidation, sulfenylation can be reversed by enzymatic reductases like thioredoxin, restoring cysteine thiols and preventing irreversible damage. Environmental factors, including elevated ROS from mitochondrial dysfunction or high glucose, drive the rate of these changes, with glycation and oxidation being particularly sensitive to metabolic imbalances. In vitro, non-enzymatic modifications are common during protein isolation and analysis, often as unintended artifacts or purposeful labels. For example, iodoacetamide alkylates free thiols in denatured proteins during workflows, preventing reformation and enabling mass spectrometry-based identification, though over-alkylation can occur spontaneously under alkaline conditions. Nitrosylation, the addition of to cysteines, can also arise artifactually during sample preparation if donors are present, mimicking physiological S-nitrosylation but complicating studies. These in vitro events highlight the need for controlled conditions to distinguish true biological modifications from procedural ones. Physiologically, non-enzymatic PTMs play significant roles in aging and ; , a form of oxidative modification where reactive carbonyls from or glycoxidation adduct to lysines, arginines, or cysteines, accumulates in aging tissues and correlates with in neurodegenerative diseases. In , glycation-derived AGEs contribute to and by inducing and . Overall, these modifications underscore the interplay between metabolic environment and protein , with implications for therapeutic strategies targeting ROS scavengers or inhibitors to mitigate age-related decline.

Conjugations and Structural Alterations

Conjugations in post-translational modifications involve the covalent attachment of proteins or peptides to target proteins, often mediating signaling, localization, or degradation pathways. These processes typically require enzymatic cascades similar to ubiquitination but adapted for specific ubiquitin-like proteins (UBLs). Ubiquitination exemplifies this, where ubiquitin is conjugated to lysine residues on target proteins via a three-enzyme cascade: E1-activating enzymes form a thioester bond with ubiquitin's C-terminus using ATP, transferring it to E2-conjugating enzymes, which then interact with E3 ligases to attach ubiquitin to the substrate, primarily targeting proteins for proteasomal degradation. SUMOylation, another key conjugation, attaches small ubiquitin-like modifier (SUMO) proteins to lysine residues, influencing nuclear import and stability; the process mirrors ubiquitination but uses distinct E1 (SAE1/SAE2), E2 (Ubc9), and E3 enzymes, with SUMO promoting nuclear targeting of transcription factors and DNA repair proteins. Neddylation conjugates neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) to cullin subunits of cullin-RING E3 ligases (CRLs), activating them for ubiquitin transfer; this involves E1 (NAE1/UBA3), E2 (UBE2M or UBE2F), and E3 (DCNLs) enzymes, enhancing CRL-mediated ubiquitination of substrates in cell cycle regulation. Peptide and protein linkages further diversify protein function through membrane anchoring or stabilization. (GPI) anchors are preformed glycolipids transferred en bloc to the C-terminal residue of nascent proteins by the transamidase complex (GPI-T), tethering proteins to the outer leaflet of the plasma membrane and facilitating in eukaryotes. bond formation, a covalent linkage between thiols, occurs via thiol-disulfide exchange catalyzed primarily by (PDI) in the ; PDI's active-site s shuttle electrons, forming intramolecular or intermolecular bonds that stabilize protein tertiary and structures, with correcting mispaired bonds during folding. Structural alterations encompass changes that reshape protein architecture post-synthesis, enabling maturation and functional diversity. Proteolytic cleavage removes specific segments, such as , which direct proteins to the secretory pathway; signal peptidases (e.g., SPC18 complex in eukaryotes) cleave the N-terminal after translocation into the ER, exposing the mature protein domain for further processing. These modifications generate protein isoforms independently of , enhancing complexity. For instance, sequential proteolytic cleavages convert preproinsulin to mature insulin: signal peptidase removes the signal peptide in the ER, followed by prohormone convertases (PC1/3 and PC2) excising the in immature secretory granules, and carboxypeptidase E trimming basic residues, yielding the bioactive A- and B-chain heterodimer linked by disulfides. Such processing diversifies functional forms from a single precursor, critical for activation and storage.

Specific Types of PTMs

Addition of Functional Groups

Post-translational modifications involving the addition of functional groups to proteins introduce chemical moieties that enhance specific properties, such as membrane association, enzymatic activity, or regulatory signaling, thereby modulating protein localization, stability, and interactions. These modifications typically occur on side chains and are often reversible, allowing dynamic control over protein function in response to cellular needs. Unlike inherent structural changes to amino acids, these additions incorporate exogenous groups that directly influence biophysical attributes like or reactivity. One prominent example is palmitoylation, where a 16-carbon saturated , palmitate, is covalently attached to residues via a reversible bond. This modification is catalyzed by palmitoyl acyltransferases (PATs) of the DHHC family and can be removed by thioesterases, enabling rapid cycling of protein localization. Palmitoylation increases the hydrophobicity of the modified protein, facilitating its anchoring to cellular membranes and trafficking to specific compartments like the plasma membrane or Golgi apparatus. For instance, in ion channels and G-protein coupled receptors, this PTM regulates membrane association and signaling efficiency. Functional groups that enhance catalytic activity include lipoylation and phosphopantetheinylation, which equip enzymes with cofactors essential for metabolic processes. Lipoylation involves the attachment of —a dithiolane ring-containing —to the epsilon-amino group of residues in key dehydrogenases, such as the E2 subunits of and alpha-ketoglutarate dehydrogenase complexes. This modification, performed by lipoate protein ligases, introduces a swinging arm that facilitates acyl transfer and reactions, thereby activating oxidative in mitochondria. The group alters the local sterics and redox potential, enabling substrate channeling and preventing reactive intermediate leakage. Similarly, phosphopantetheinylation modifies acyl carrier proteins (ACPs) by transferring the 4'-phosphopantetheine moiety from to a conserved serine residue, converting apo-ACPs to holo-forms. This PTM, catalyzed by 4'-phosphopantetheinyl transferases (PPTs), provides a flexible phosphopantetheine arm that tethers acyl intermediates during and polyketide . The attachment enhances the protein's ability to shuttle substrates between catalytic domains, altering steric accessibility and promoting efficient multi-enzyme complex function in biosynthetic pathways. Regulatory small groups, such as those from ubiquitin-like modifiers and nucleotide-derived moieties, fine-tune protein activity in stress responses. , an product, functions as a ubiquitin-like modifier that conjugates to residues on target proteins via a intermediate, a process termed ISGylation. This PTM is crucial for the innate antiviral immune response, where it stabilizes interferon signaling proteins and inhibits viral replication by altering target protein stability and interactions. For example, ISG15 modification of cellular factors like enhances type I production, while its conjugation to viral proteins disrupts their function. ADP-ribosylation adds adenosine diphosphate-ribose (ADPr) units from NAD+ to amino acid residues, primarily glutamates, aspartates, or serines, through the action of poly(ADP-ribose) polymerases (PARPs). In DNA repair signaling, PARP1 and PARP2 rapidly PARylate histones and repair factors at damage sites, recruiting repair machinery like XRCC1 and altering chromatin structure to facilitate access. This modification introduces negative charge from the phosphate groups, which repels nucleosomes and promotes strand break resolution, while also serving as a scaffold for protein recruitment. Mono-ADP-ribosylation provides finer regulation, modulating enzyme activities without extensive chain formation. Collectively, these additions profoundly impact protein behavior by modulating hydrophobicity, charge distribution, and steric hindrance. Palmitoylation's chain boosts partitioning, driving vesicular trafficking and compartmentalization. Cofactor attachments like or phosphopantetheine optimize geometry for , enhancing reaction rates in metabolic hubs. Regulatory modifications such as ISG15 or ADPr introduce electrostatic changes that influence protein-protein affinities, enabling rapid in immune or repair pathways. These alterations ensure precise spatiotemporal control, preventing dysregulation that could lead to metabolic imbalances or unrepaired genomic damage.

Chemical Modifications of Amino Acids

Chemical modifications of amino acids encompass post-translational alterations that directly transform the intrinsic structure of residues within proteins, such as changes to side chains or the peptide backbone, without the attachment of external functional groups. These modifications, often enzymatic, can alter physicochemical properties like charge, hydrophobicity, or conformation, thereby influencing protein stability, interactions, and degradation. Examples include conversions that neutralize charged residues or introduce stereochemical variations, which are critical in specific biological contexts such as assembly and aging processes. Side-chain modifications frequently involve targeted enzymatic conversions that affect residue functionality. , catalyzed by peptidylarginine deiminase (PAD) enzymes, converts positively charged residues to neutral , reducing the net positive charge of the protein and potentially disrupting electrostatic interactions. This calcium-dependent reaction, mediated by a family of PAD isozymes (EC 3.5.3.15), occurs in various mammalian tissues and is implicated in processes like and . For instance, PAD activation during leads to protein , contributing to nuclear condensation and decondensation. Another prominent side-chain alteration is arginylation, where arginyltransferase 1 (ATE1) transfers an residue to the of target proteins, marking them for ubiquitin-dependent degradation via the pathway. ATE1 recognizes destabilizing N-terminal residues such as aspartate, glutamate, or oxidized , conjugating to facilitate proteasomal breakdown. This modification is essential for cellular , as evidenced by ATE1 mice exhibiting lethal cardiovascular defects due to impaired vascular remodeling and . Backbone modifications often stabilize structural elements or regulate processing. Prolyl hydroxylation introduces a hydroxyl group to the 4-position of residues in , catalyzed by prolyl 4-hydroxylases (P4Hs), which require ascorbic acid, α-ketoglutarate, and iron as cofactors. This modification is vital for the thermal stability of the triple helix, as enhances hydrogen bonding and rigidity; defects in P4H activity lead to under-hydroxylated prone to degradation and associated with disorders like . In collagens, approximately 10-20% of residues undergo this , primarily in Y positions of Gly-X-Y repeats. Pyroglutamate formation involves the cyclization of N-terminal glutamate (or glutamine) to pyroglutamic acid (pE), a spontaneous or enzyme-facilitated process that neutralizes the α-amino group and forms a five-membered lactam ring. This non-enzymatic conversion occurs under physiological conditions (pH 7.4, 37°C) and is observed in recombinant proteins like human IgG2 antibodies, where it accumulates over time in vivo following administration. The modification can influence protein solubility and stability, with rates varying by chain (e.g., faster in heavy chains due to structural accessibility). Racemization and represent non-enzymatic or rare enzymatic stereochemical shifts that invert or rearrange the . formation is uncommon in eukaryotic proteins but occurs post-translationally in bacterial ribosomally synthesized peptides, where enzymes epimerize specific L-residues to D-configuration, enhancing resistance to and altering bioactivity. For example, in like , confer structural rigidity and specificity. In eukaryotes, aspartate to β-isoaspartate or D-aspartate accumulates in long-lived proteins during aging, disrupting backbone geometry and function; in human lens αA-crystallin, Asp-151 isomerization increases from negligible in newborns to over 50% of total Asp by age 80, correlating with formation and reduced chaperone activity. These chemical modifications profoundly impact protein function, particularly through charge alterations that modulate interactions. Citrullination's charge neutralization, for instance, enhances matrix metalloproteinase-9 (MMP-9) affinity for substrates like and promotes its activation in extracellular contexts, as seen in neutrophil-rich environments like sputum, thereby influencing tissue remodeling. Similarly, prolyl in extracellular matrix proteins like ensures structural integrity under mechanical stress, while isomerization in aging tissues impairs and aggregation resistance. Such changes highlight how subtle atomic rearrangements can drive physiological regulation or pathological states.

Protein-Protein Conjugations

Protein-protein conjugations represent a class of post-translational modifications (PTMs) in which proteins or peptides are covalently attached to target proteins, often to regulate stability, localization, or signaling pathways. These modifications typically involve ubiquitin-like proteins (UBLs) or specialized enzymes that form isopeptide bonds between residues or other reactive sites, enabling precise control over protein function. Unlike smaller chemical group additions, these large biomolecular attachments can create complex assemblies, such as polyprotein chains, that serve as signals for degradation or cellular communication. The ubiquitin family exemplifies protein-protein conjugations, with ubiquitination being the most studied process in eukaryotes. , a 76-amino-acid protein, is covalently linked to target lysines on substrate proteins through a multi-step enzymatic cascade. This begins with activation by E1 enzymes, which form a bond with 's using ATP, followed by transfer to E2 conjugating enzymes, and finally ligation to the substrate by E3 ligases, which confer specificity via adaptor domains that recognize particular substrates. Polyubiquitin chains form when additional link to residues on the initial ; K48-linked chains typically signal proteasomal degradation by the 26S , while K63-linked chains promote non-degradative roles, such as signaling and . In prokaryotes, pupylation serves an analogous function, where the intrinsically disordered prokaryotic ubiquitin-like protein (Pup) is deamidated by Dop and conjugated to target by PafA, marking proteins for degradation by bacterial , particularly in actinobacteria like to aid survival under stress. Other notable protein-protein conjugations include transglutamination and sortase-mediated tagging. Transglutaminases (TGs), such as factor XIIIa in mammals, catalyze the formation of isopeptide bonds between and residues on proteins, cross-linking during blood clotting to stabilize hemostatic plugs and prevent excessive . In bacteria, sortases like sortase A from facilitate transpeptidation by cleaving the LPXTG motif on surface proteins and linking the resulting acyl intermediate to peptidoglycan glycines, enabling anchoring and display. These processes highlight the evolutionary conservation of protein conjugation for structural and functional adaptations. The specificity of these conjugations arises from the enzymatic cascades and adaptor proteins; for instance, ligases in ubiquitination interact with E2-ubiquitin complexes through domains like RING or HECT, ensuring targeted modification, while bacterial systems like pupylation rely on fewer components for efficiency. Beyond degradation, these PTMs play key regulatory roles, such as in where the LC3 conjugation system—analogous to ubiquitination—involves E1-like Atg7 and E2-like Atg3 enzymes attaching processed LC3 to on autophagosomal membranes, facilitating cargo engulfment and lysosomal degradation. Similarly, the UBL FAT10, activated by UBA6 and conjugated via USE1, modulates immune responses by enhancing and downregulating signaling through non-covalent interactions with pattern recognition receptors like RIG-I.

Prevalence and Analysis

Statistical Distribution

Large-scale proteomic analyses have revealed that post-translational modifications (PTMs) are highly prevalent in the human , with over 2,000,000 experimentally validated PTM sites identified across approximately 20,000 protein-coding genes, expanding the functional proteome to more than 1,000,000 proteoforms. Among the most common PTMs, dominates in terms of site frequency, accounting for the majority of identified modifications, with estimates suggesting that at least 70% of human proteins undergo phosphorylation at some point during their lifecycle. , particularly N-linked forms, is especially abundant in secreted and membrane proteins, affecting nearly all such proteins and comprising a significant portion of the proteome's mass despite occurring on fewer sites overall. Ubiquitination, often signaling protein degradation, similarly impacts around 70% of proteins, with over 60,000 sites documented, primarily on residues. PTM distribution varies markedly by amino acid residue, reflecting the chemical properties targeted by modifying enzymes. Serine and residues are the primary sites for , comprising over 70% of all such modifications, with serine alone accounting for more than 95% in certain tissues like the human heart; is less frequent but critical in signaling pathways. residues are hotspots for multiple PTMs, including (affecting ~70% of proteins), , and ubiquitination, with tens of thousands of sites each. is predominantly modified by N-linked , contributing to the structural diversity of extracellular proteins. These statistics derive from comprehensive mass spectrometry-based surveys, such as those cataloged in databases like dbPTM and Swiss-Prot (as of 2025, dbPTM annotates over 2.79 million PTM sites, including more than 100,000 sites after false-positive corrections), which have annotated hundreds of thousands of sites from tissues. Evolutionary conservation is high for many PTM sites, particularly motifs, underscoring their functional importance. PTM prevalence also exhibits tissue-specific and condition-dependent variations; for instance, is markedly elevated in plasma proteins compared to intracellular ones, while oxidative modifications on and increase under cellular stress.

Detection Methods and Tools

Post-translational modifications (PTMs) are detected through a combination of experimental and computational approaches that enable the identification, localization, and quantification of modification sites on proteins. Experimental methods primarily rely on techniques that isolate and analyze modified proteins, while computational tools aid in , annotation, and . These methods address the diversity of PTMs, from covalent additions like to more complex structural changes, though challenges such as low and persist. Mass spectrometry (MS) stands as the cornerstone for comprehensive PTM detection, particularly liquid chromatography-tandem MS (LC-MS/MS), which fragments peptides to map modification sites with high resolution. For instance, LC-MS/MS identifies sites by detecting mass shifts (e.g., +80 Da for groups) and localizing them via fragmentation patterns, often achieving site-specific accuracy above 95% when coupled with advanced algorithms. Enrichment strategies enhance sensitivity for low-abundance PTMs; (TiO2) selectively captures phosphopeptides by binding groups under acidic conditions, improving detection by up to 100-fold in complex samples. Antibody-based similarly enriches specific PTMs like ubiquitination or , prior to MS analysis, as demonstrated in studies of modifications where it isolated acetylated lysines for subsequent sequencing. Western blotting complements MS by providing targeted detection using site-specific antibodies that recognize epitopes altered by PTMs, such as anti-phospho-Ser/Thr antibodies, offering qualitative confirmation in cellular lysates with high specificity but limited throughput. Biochemical assays provide functional insights into PTM dynamics and activities. activity assays, such as those using radiolabeled ATP or luminescent substrates, measure events by quantifying incorporated phosphate, with sensitivity down to picomolar levels for specific kinase-substrate pairs. Fluorescence-based labeling techniques, including clickable probes for or proximity ligation assays, track PTM occurrence in live cells; for example, bioorthogonal labeling with alkyne-modified acyl groups enables imaging and quantification of nascent acetylations via , revealing temporal dynamics in signaling pathways. These assays are particularly useful for validating MS-identified sites and studying PTM reversibility through or deubiquitinase activity measurements. Computational tools and databases facilitate PTM prediction and curation from experimental data. Prediction software like NetPhos employs neural networks to forecast serine/ phosphorylation sites based on sequence motifs, achieving prediction accuracies of 80-90% for known kinase consensus sequences. The GPS (Group-based Prediction System) tool extends this by assigning -specific motifs to potential sites, integrating evolutionary conservation for improved specificity in eukaryotic proteins. For data storage and analysis, PhosphoSitePlus serves as a comprehensive repository for and PTMs, aggregating over 290,000 phosphorylation sites from MS and low-throughput experiments as of 2024, with annotations on regulatory contexts. provides curated PTM annotations across proteomes, linking modifications to functional outcomes via cross-references, covering more than 100,000 entries with evidence codes for reliability. Additional resources include dbPTM (as of the 2025 update, integrating over 2.79 million PTM sites from multiple databases with structural and disease associations); PTMcode, focused on PTM crosstalk predictions through residue co-occurrence analysis; and iPTMnet, which models PTM interaction networks using graph-based approaches to infer regulatory hierarchies. These tools collectively enable large-scale , though they require experimental validation due to false positive rates in predictions. Despite these advances, detecting labile PTMs remains challenging; for example, phosphorylation can be lost during MS sample preparation due to acid lability, necessitating mild ionization techniques like to preserve modifications. Overall, integrating orthogonal methods—such as MS with biochemical validation—enhances PTM discovery, supporting systems-level studies of protein .

Applications and Examples

Role in Cellular Processes

Post-translational modifications (PTMs) are integral to cellular processes, enabling dynamic of protein activity, localization, and interactions in response to environmental cues. These modifications act as molecular switches that fine-tune enzymatic functions and signaling fidelity, ensuring coordinated cellular responses such as growth, , and division. In signaling pathways, serves as a primary PTM, facilitating rapid through cascades like the (MAPK) and (PI3K) pathways, which control cell growth and proliferation. The MAPK pathway involves sequential phosphorylation events where receptor kinases activate Ras , leading to the phosphorylation and activation of Raf, MEK, and ERK kinases, thereby propagating signals from the cell surface to the nucleus to regulate . Similarly, in the PI3K pathway, phosphorylation activates Akt, which modulates downstream targets to promote cell survival and metabolism, with dynamic on/off switches provided by kinases and phosphatases that allow reversible control of signal amplitude and duration. Protein trafficking relies on PTMs to direct the movement, sorting, and quality control of proteins through organelles. Glycosylation, initiated in the endoplasmic reticulum (ER) and matured in the Golgi apparatus, adds carbohydrate moieties that facilitate protein folding, ER quality control via the calnexin/calreticulin cycle, and subsequent secretion by marking properly folded proteins for vesicular transport. Ubiquitination, particularly monoubiquitination, acts as a sorting signal for endocytosis, recruiting endocytic adaptors like EPS15 to internalize plasma membrane receptors into clathrin-coated pits, thereby regulating their trafficking to lysosomes or recycling endosomes. In and stress responses, PTMs adjust enzymatic activities to maintain and detect changes. Deacetylation of mitochondrial proteins, such as enzymes in the tricarboxylic acid cycle and fatty acid oxidation, modulates their catalytic efficiency; for instance, deacetylation of isocitrate dehydrogenase 2 by SIRT3 enhances its activity, thereby increasing NADPH production to support defenses under conditions like . Protein oxidation, involving or residues, functions in sensing by forming reversible bonds or sulfenic acids that alter protein conformation, enabling stress-responsive pathways like the Nrf2 response to mitigate oxidative damage. Cell cycle control is tightly governed by PTMs that synchronize progression through checkpoints. Phosphorylation and dephosphorylation of cyclins by cyclin-dependent kinases (CDKs) and phosphatases regulate transitions; for example, CDK1 phosphorylates to activate it during G2/M phase, while dephosphorylation by phosphatases commits the cell to , ensuring orderly replication and division. SUMOylation targets checkpoint proteins like topoisomerase II and aurora kinases, stabilizing their localization and activity at kinetochores to prevent chromosomal instability during .

Case Studies in Disease and Regulation

In cancer, aberrant post-translational modifications such as hyperphosphorylation of the (EGFR) drive tumor progression by promoting uncontrolled cell proliferation and survival signaling. EGFR, a , undergoes autophosphorylation upon ligand binding, but in many tumors, mutations or overexpression lead to constitutive and hyperactivation of downstream pathways like PI3K/AKT and MAPK, contributing to oncogenesis in , , and colorectal cancers. Similarly, dysregulated , mediated by histone deacetylases (HDACs), silences tumor suppressor genes; HDAC inhibitors like restore levels, reactivating these genes and inducing in hematologic malignancies such as . Clinical trials have shown that HDAC inhibitors enhance antitumor effects when combined with other therapies, improving response rates in solid tumors by modulating as well. In neurodegenerative diseases, hyperphosphorylation of disrupts stability, leading to neurofibrillary tangles characteristic of . Kinases such as GSK-3β and CDK5 excessively phosphorylate tau at multiple sites, reducing its affinity for and promoting aggregation into insoluble filaments that impair neuronal and contribute to synaptic dysfunction and cell death. In , oxidative post-translational modifications of , including and carbonylation at and residues, accelerate its misfolding and aggregation into Lewy bodies, exacerbating dopaminergic neuron loss and motor symptoms. These modifications arise from in the , enhancing alpha-synuclein's propensity for fibril formation and propagation. Post-translational modifications also play critical roles in immune dysregulation, as seen in where of joint proteins triggers . , catalyzed by peptidylarginine deiminases (PADs) under conditions, converts to , altering protein charge and exposing neoepitopes recognized by anti-citrullinated protein antibodies (ACPAs), which drive synovial and bone erosion. In cancer and chronic infections, N- of PD-1 enhances the binding affinity of certain blocking antibodies, such as camrelizumab, which interacts with the N58 glycan to more effectively inhibit PD-1:PD-L1 interactions, thereby reducing T-cell exhaustion. Additionally, of PD-L1, including sialylated forms, can stabilize its surface expression and promote immune evasion. Therapeutic strategies exploiting PTMs have revolutionized treatment, particularly through targeted degradation and kinase inhibition. Proteolysis-targeting chimeras (PROTACs) hijack the ubiquitination machinery by recruiting ligases to tag proteins like or for proteasomal degradation, offering efficacy against cancers resistant to traditional inhibitors and advancing clinical trials for and hematologic malignancies. As of 2025, PROTACs continue to advance, with vepdegestrant (ARV-471), an degrader, having an NDA submitted to the FDA based on phase 3 trial results showing efficacy in ER-positive . Likewise, , a selective inhibitor of BCR-ABL , transformed chronic management by blocking the constitutively active in 95% of chronic-phase patients, inducing durable remissions and serving as a paradigm for PTM-targeted therapies.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8040245/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3915910/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC10591476/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8365368/
  5. https://www.nature.com/articles/s41467-024-51071-9
  6. https://www.sciencedirect.com/topics/neuroscience/posttranslational-modification
  7. https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/overview-post-translational-modification.html
  8. https://www.nature.com/articles/cr2013151
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC7226565/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3974995/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC8721491/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC4320298/
  13. https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.14014
  14. https://www.nature.com/articles/s41467-023-35795-8
  15. https://pubs.acs.org/doi/10.1021/acs.chemrev.7b00756
  16. https://academic.oup.com/nar/article/53/D1/D554/7779354
  17. https://www.mcponline.org/article/S1535-9476(21)00101-8/fulltext
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4019982/
  19. https://www.jbc.org/article/S0021-9258(23)00259-4/fulltext
  20. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1240115/full
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC8358657/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC6054547/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC7966921/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC5574318/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7611092/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10152985/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC6962057/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC10200003/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC2588348/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC10062008/
  31. https://www.nature.com/articles/s41418-020-00703-w
  32. https://www.nature.com/articles/s41392-024-01800-9
  33. https://www.nature.com/articles/s12276-020-0401-5
  34. https://www.nature.com/articles/s41392-022-01245-y
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3594063/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3058972/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4240533/
  38. https://www.nature.com/articles/s41420-025-02718-z
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC5965299/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC2804320/
  41. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/phosphopantetheine
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10891536/
  43. https://www.nature.com/articles/s12276-022-00872-3
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC7097117/
  45. https://www.sciencedirect.com/science/article/pii/S1672022916300705
  46. https://genesdev.cshlp.org/content/31/2/101.full
  47. https://www.jbc.org/article/S0021-9258%2823%2902425-0/fulltext
  48. https://genomemedicine.biomedcentral.com/articles/10.1186/gm424
  49. https://pubmed.ncbi.nlm.nih.gov/14579251/
  50. https://pubmed.ncbi.nlm.nih.gov/31932199/
  51. https://pubmed.ncbi.nlm.nih.gov/12098698/
  52. https://pubmed.ncbi.nlm.nih.gov/33228359/
  53. https://pubmed.ncbi.nlm.nih.gov/19160570/
  54. https://pubmed.ncbi.nlm.nih.gov/27129244/
  55. https://pubmed.ncbi.nlm.nih.gov/21282104/
  56. https://pubmed.ncbi.nlm.nih.gov/16828250/
  57. https://pubmed.ncbi.nlm.nih.gov/1471255/
  58. https://pubmed.ncbi.nlm.nih.gov/10600491/
  59. https://pubmed.ncbi.nlm.nih.gov/33157227/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC8607428/
  61. https://journals.biologists.com/jcs/article/129/5/875/56021/Ubiquitin-chain-diversity-at-a-glance
  62. https://bmcbiol.biomedcentral.com/articles/10.1186/1741-7007-10-95
  63. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.07-0602ufm
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC3314344/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC7129593/
  66. https://journals.biologists.com/jcs/article/133/14/jcs246041/224878/The-ubiquitin-like-modifier-FAT10-much-more-than-a
  67. https://portlandpress.com/biochemj/article/480/16/1241/233398/A-global-view-of-the-human-post-translational
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC3861698/
  69. https://pubmed.ncbi.nlm.nih.gov/19196183/
  70. https://www.nature.com/articles/srep00090
  71. https://www.nature.com/articles/s41598-021-81986-y
  72. https://academic.oup.com/nar/advance-article-pdf/doi/10.1093/nar/gkae1005/60586513/gkae1005.pdf
  73. https://www.nature.com/articles/s41589-024-01613-5
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC8197917/
  75. https://www.nature.com/articles/s41573-021-00371-6
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC4072215/
  77. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.00381/full
  78. https://www.jci.org/articles/view/25422
  79. https://www.embopress.org/doi/10.15252/embr.202051444
  80. https://aacrjournals.org/cancerres/article/80/11/2298/641090/Targeting-Glycosylated-PD-1-Induces-Potent
  81. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01818
  82. https://ashpublications.org/blood/article/105/7/2640/20208/The-development-of-imatinib-as-a-therapeutic-agent
Add your contribution
Related Hubs
User Avatar
No comments yet.